Evidence map›Paper›PMID 31146753›Full record

ArticleWorld journal of surgical oncology2019

Which papillary thyroid microcarcinoma should be treated as "true cancer" and which as "precancer"?

Krzysztof Kaliszewski, Dorota Diakowska, Beata Wojtczak, Zdzisław Forkasiewicz, Dominika Pupka, Łukasz Nowak, Jerzy Rudnicki

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04376203 (What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development?), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04376203 unknown statusnot on this mapstarted 2020, after this paper: background citation

What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development?

TypeobservationalSponsorUniversity of IoanninaRan2020 to 2023Enrolled40ConditionsPapillary Thyroid Microcarcinoma, MicrobiomeArmsThyroidectomy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Krzysztof KaliszewskiDepartment of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska Street 213, 50-556, Wroclaw, Poland. krzysztofkali@wp.pl.ORCID http://orcid.org/0000-0002-3291-5294
Dorota DiakowskaDepartment of Nervous System Diseases, Faculty of Health Science, Wroclaw Medical University, Wroclaw, Poland.
Beata WojtczakDepartment of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska Street 213, 50-556, Wroclaw, Poland.
Zdzisław ForkasiewiczDepartment of Surgery Didactics, Wroclaw Medical University, Wroclaw, Poland.
Dominika PupkaDepartment of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska Street 213, 50-556, Wroclaw, Poland.
Łukasz NowakDepartment of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska Street 213, 50-556, Wroclaw, Poland.
Jerzy RudnickiDepartment of General, Minimally Invasive and Endocrine Surgery, Wroclaw Medical University, Borowska Street 213, 50-556, Wroclaw, Poland.
Wroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPapillary thyroid microcarcinoma (PTMC) generally is a cancer with excellent prognosis, but the term "cancer" sounds severe and harsh, which can elicit emotional and physical responses from patients. To eliminate the word "cancer," the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced. However, not all PTMCs can be classified as NIFTP. Sometimes, very aggressive PTMC cases might be observed. Some authors suggest that one of the risk factors for poor prognosis is lymph node metastasis. The aim of the study was to evaluate some clinicopathological features of PTMC as the risk factors for lymph node metastasis. MATERIAL AND

methodsWe performed a retrospective chart review and selected 177 patients with PTMC. To analyze the cases with potentially aggressive behavior, we enrolled PTMC patients with lymph node metastases (pN1, central, and/or lateral) and evaluated some of their clinicopathological features.

resultsThe logistic regression analysis results demonstrated significantly higher rates of multifocal or bilateral tumor occurrence in the PTMC patients with pN1 than in the patients with pN0 (P < 0.0001 for both). In addition, the occurrence of thyroid tumors with sizes above 0.5 cm was a significant risk factor for lymph node metastasis (P < 0.0001). The results of the ROC analyses showed that the presence of multifocal or bilateral tumors and tumor sizes above 0.5 cm were significant predictors of lymph node metastasis (P < 0.0001 for all).

conclusionsMultifocal and bilateral PTMC tumors with diameters above 0.5 cm should be treated aggressively as "true cancer" and might benefit from lymph node dissection. Unifocal PTMC tumors with diameters equal to or below 0.5 cm may be treated less aggressively.

Indexed as

Carcinoma, PapillaryFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph Node ExcisionMaleMiddle AgedPrecancerous ConditionsPrognosisRetrospective StudiesThyroidectomyThyroid NeoplasmsAggressivenessMetastasisPapillary thyroid microcarcinoma

Identifiers

PMID31146753
PMCPMC6543635
OpenAlexW2946832405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.